Memory Aid for Informed Consent in Alzheimer's Research

This study has been completed.
Sponsor:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00105612
First received: March 15, 2005
Last updated: December 23, 2009
Last verified: December 2009

March 15, 2005
December 23, 2009
September 2004
March 2007   (final data collection date for primary outcome measure)
MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR) to quantify decision making abilities
Same as current
Complete list of historical versions of study NCT00105612 on ClinicalTrials.gov Archive Site
Participant competency
Same as current
 
 
 
Memory Aid for Informed Consent in Alzheimer's Research
Improving Informed Consent in Alzheimer's Disease Research

The purpose of this trial is to test whether a memory and organizational aid in the form of a document that summarizes and simplifies a study's key points can improve the decision-making abilities and competency of mild to early moderate Alzheimer's disease (AD) patients.

Studies of mild to moderate Alzheimer's disease (AD) patients reveal substantial variation in their ability to participate in an informed consent process. No published data show techniques that help an AD patient to participate in an informed consent. This research will address this issue by performing a randomized trial to test whether a memory and organizational aid can improve the decision-making abilities and competency of AD patients.

This study will recruit 80 patients with mild to early moderate AD, and 30 non-demented elderly persons. The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home. The AD patients will be randomized to receive either the standard informed consent process or the intervention of the standard informed consent process plus the memory and organizational aid. All non-demented elderly individuals will receive the standard informed consent process. The interviewer will administer the protocol to participants and ask questions that will assess participant capacity to understand, appreciate, reason, and make a choice concerning enrollment in the hypothetical study.

Interventional
 
Allocation: Randomized
Endpoint Classification: Efficacy Study
  • Alzheimer's Disease
  • Aging
  • Device: Memory and Organizational Aid
  • Behavioral: Standard Informed Consent Process
    The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
110
March 2007
March 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Live within one hour drive of the University of Pennsylvania's Memory Disorders Clinic
  • Education equivalent to 6th grade level
  • Corrected visual acuity of at least 20/70
  • Speak English
  • Diagnosed with possible or probable AD, or non-demented
  • MMSE (Mini Mental State Exam) >= 18
Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00105612
IA0070, 1R01AG020627-01A2
 
 
National Institute on Aging (NIA)
 
Principal Investigator: Jason Karlawish, MD University of Pennsylvania Institute on Aging
National Institute on Aging (NIA)
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP